0001209191-21-009368.txt : 20210210
0001209191-21-009368.hdr.sgml : 20210210
20210210175651
ACCESSION NUMBER: 0001209191-21-009368
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210208
FILED AS OF DATE: 20210210
DATE AS OF CHANGE: 20210210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'Brien Patrick
CENTRAL INDEX KEY: 0001627183
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38042
FILM NUMBER: 21615454
MAIL ADDRESS:
STREET 1: 225 S. LAKE AVENUE SUITE 1050
CITY: PASADENA
STATE: CA
ZIP: 91101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARROWHEAD PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000879407
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460408024
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 177 E COLORADO BLVD
STREET 2: SUITE 700
CITY: PASADENA
STATE: CA
ZIP: 91105
BUSINESS PHONE: 626-696-4702
MAIL ADDRESS:
STREET 1: 177 E COLORADO BLVD
STREET 2: SUITE 700
CITY: PASADENA
STATE: CA
ZIP: 91105
FORMER COMPANY:
FORMER CONFORMED NAME: ARROWHEAD RESEARCH CORP
DATE OF NAME CHANGE: 20040112
FORMER COMPANY:
FORMER CONFORMED NAME: INTERACTIVE GROUP INC
DATE OF NAME CHANGE: 20020509
FORMER COMPANY:
FORMER CONFORMED NAME: INTERACTIVE INC
DATE OF NAME CHANGE: 19940224
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-08
0
0000879407
ARROWHEAD PHARMACEUTICALS, INC.
ARWR
0001627183
O'Brien Patrick
177 E. COLORADO BLVD
SUITE 700
PASADENA
CA
91105
0
1
0
0
General Counsel
Common Stock
2021-02-08
4
M
0
90000
5.22
A
383375
D
Common Stock
2021-02-08
4
S
0
7961
86.72
D
375414
D
Common Stock
2021-02-08
4
S
0
31255
88.08
D
344159
D
Common Stock
2021-02-08
4
S
0
45348
88.88
D
298811
D
Common Stock
2021-02-08
4
S
0
5436
89.66
D
293375
D
Stock Option (right to buy)
5.22
2021-02-08
4
M
0
90000
0.00
D
2015-06-02
2024-12-02
Common Stock
90000
60000
D
The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.26 to
$87.11, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead
Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares
sold at each separate price within the ranges set forth in this footnote of this Form 4.
The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.43 to
$88.42, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead
Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares
sold at each separate price within the ranges set forth in this footnote of this Form 4.
The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.44 to
$89.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead
Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares
sold at each separate price within the ranges set forth in this footnote of this Form 4.
The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.45 to
$89.85, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead
Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares
sold at each separate price within the ranges set forth in this footnote of this Form 4.
Represents the first vesting date. Option vested over four years from date of grant.
/s/Patrick O'Brien
2021-02-10